Parkinson's disease Levodopa-induced dyskinesia (PD-LID) - Epidemiology Forecast - 2032

DelveInsight's 'Parkinson's disease Levodopa-induced dyskinesia (PD-LID) - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Parkinson's disease Levodopa-induced dyskinesia in the United States, Japan, EU4 (Germany, Spain, Italy, France) and the UK.

Parkinson's disease Levodopa-induced dyskinesia (PD-LID): Disease Understanding

Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Overview

According to the Parkinson's Foundation, Parkinson's disease (PD) is a neurodegenerative disorder that affects dopamine-producing (dopaminergic) neurons predominately in a specific area of the brain called the substantia nigra.

Treatment involves pharmacologic approaches (typically with levodopa preparations prescribed with or without other medications) and nonpharmacologic approaches (such as exercise, occupational, and speech therapies). Approaches such as deep brain stimulation (DBS) and treatment with levodopa-carbidopa enteral suspension can help individuals with medication-resistant tremors, worsening symptoms when the medication wears off, and dyskinesias.

Levodopa (L-DOPA) is the most effective drug for treating PD, but motor fluctuations and dyskinesia complicate its long-term use. Dyskinesia may be mild at the beginning but may progress to become a disabling symptom and may interfere with the quality of life. There are three types of dyskinesias identified to date, off-period dystonia, peak dose dyskinesia, and diphasic dyskinesia. Off-time dyskinesia is usually encountered during the night or early morning. Thus, the administration of L-DOPA formulations having a longer half-life at night can effectively treat off-time dyskinesia. However, diphasic dyskinesia is treated by increasing the dose of dopaminergic drugs administered; contrarily, peak dose dyskinesia is generally performed by reducing the dose of the dopaminergic drug administered.

The treatment strategy includes identifying the kind of dyskinesia and tailoring treatment accordingly. Peak-dose dyskinesia is treated mainly by reducing individual doses of levodopa and adding amantadine and dopamine agonists, whereas off-period dystonia often responds to baclofen and botulinum toxin injections. Diphasic dyskinesias are the most difficult to treat, particularly in patients with young-onset PD. While fractionation of levodopa dosage is the most frequently utilized strategy, many patients require DBS to control their troublesome motor fluctuations and LIDs. Various emerging drugs currently in development promise to provide better control of LIDs and other levodopa-related complications shortly.

Epidemiology

The Parkinson's disease levodopa-induced dyskinesia epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Parkinson's disease levodopa-induced dyskinesia epidemiology segmented as the number of patients developing PD-LID and type-specific cases of PD-LID. The report includes the prevalent Parkinson's disease levodopa-induced dyskinesia in the 7MM covering the United States, Japan, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom from 2019 to 2032.

Country-wise Parkinson's disease Levodopa-induced dyskinesia (PD-LID) Epidemiology

The epidemiology segment also provides the Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology data and findings across the United States, Japan, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom.

The total number of cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID) in the 7MM countries were over 580,000 cases in 2021.

As per the estimates, Germany had the highest prevalent patient population of Parkinson's disease levodopa-induced dyskinesia in 2021. Among the EU4 + the UK, Germany had the highest number of cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID), with nearly 67,000 cases, followed by France in 2021. On the other hand, Spain had the lowest number of cases of Parkinson's disease levodopa-induced dyskinesia (PD-LID), with approximately 40,000 cases in 2021.

Scope of the Report:

• Parkinson's disease levodopa-induced dyskinesia (PD-LID) report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology report and model provide an overview of the risk factors and global trends of Parkinson's disease levodopa-induced dyskinesia in the seven major markets (7MM: The US, France, Germany, Italy, Spain, the UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Parkinson's disease levodopa-induced dyskinesia (PD-LID) in seven major markets covering the United States, Japan, EU4 and the UK.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
• The report describes Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology by the number of patients developing Parkinson's disease levodopa-induced dyskinesia in the 7MM.
• The report provides the segmentation of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology by the type-specific cases of Parkinson's disease levodopa-induced dyskinesia patients in the 7MM.

Report Highlights:

• 11-year Forecast of Parkinson's disease levodopa-induced dyskinesia Epidemiology
• 7MM Coverage
• Number of patients developing Parkinson's disease levodopa-induced dyskinesia
• Type-specific cases of Parkinson's disease levodopa-induced dyskinesia

KOL Views

We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What major factors will drive the change in the patient population in an indication of Parkinson's disease levodopa-induced dyskinesia during the forecast period (2019-2032)?
• What key findings about Parkinson's disease levodopa-induced dyskinesia epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients with Parkinson's disease levodopa-induced dyskinesia across the 7MM forecast period (2019-2032)?
• Among the EU4 + the UK, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
• What are the disease risk, burdens, and unmet needs of Parkinson's levodopa-induced dyskinesia (PD-LID)?
• What currently available treatments for Parkinson's disease levodopa-induced dyskinesia (PD-LID)?

Reasons to buy:

Parkinson's disease levodopa-induced dyskinesia epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Parkinson's disease levodopa-induced dyskinesia (PD-LID) market.
• Quantify patient populations in the global Parkinson's disease levodopa-induced dyskinesia (PD-LID) market to improve product design, pricing, and launch plans.
• Understand the magnitude of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) population by the number of patients developing Parkinson's disease levodopa-induced dyskinesia (PD-LID).
• Understand the magnitude of the Parkinson's disease levodopa-induced dyskinesia (PD-LID) population by its type-specific cases.
• The Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology report and model were written and developed by Master and PhD epidemiologists.
• The Parkinson's disease levodopa-induced dyskinesia (PD-LID) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 + the United Kingdom
• Japan

Study Period: 2019-2032